XIAP and acute myeloid leukemia: In this study, we therefore investigated whether or not primary AML samples are sensitive to the Smac mimetic BV6 that antagonizes XIAP, cIAP1 and cIAP2 [20], and if so, which molecular, cytogenetic or clinical markers correlate with treatment response.